Intra-Cellular's Lumateperone Brings Mixed Results In Bipolar Depression

 
• By Joseph Haas

Firm will discuss Phase III data with the US FDA, calling results from a successful Phase III monotherapy study robust despite second Phase III study's failure. Lumateperone is under review for schizophrenia, with a 27 September action date.

Bipolar disorder psychological state diagnosis concept, flat vector illustration, expressive happiness and depression, unstable patient mood, contrasting feelings with cheerful and frustrated person - Vector
Bipolar disorder is characterized by episodes of mania and depression

More from Clinical Trials

More from R&D